Blind E - Search Results

1

[Rumination and schizotypal personality traits].

Fejes ÉN, Kovács NL, Bittermann I, Blind E, Schmelowszky Á. Fejes ÉN, et al. Among authors: blind e. Ideggyogy Sz. 2023 May 30;76(5-6):149-157. doi: 10.18071/isz.76.0149. Ideggyogy Sz. 2023. PMID: 37294028 Free article. Hungarian.

2

Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective.

Kehoe T, Blind E, Janssen H. Kehoe T, et al. Among authors: blind e. Br J Clin Pharmacol. 2019 Jun;85(6):1208-1212. doi: 10.1111/bcp.13791. Epub 2018 Dec 3. Br J Clin Pharmacol. 2019. PMID: 30335197 Free PMC article. Review.

3

[Dramatic efficacy of topical ivermectin in idiopathic facial aseptic granuloma].

Blind E, Ropars N, Safa G. Blind E, et al. Ann Dermatol Venereol. 2018 Dec;145(12):792-794. doi: 10.1016/j.annder.2018.07.019. Epub 2018 Sep 6. Ann Dermatol Venereol. 2018. PMID: 30197052 French. No abstract available.

4

Ivermectin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.

Kerneuzet I, Blind E, Darrieux L, Moreau S, Safa G. Kerneuzet I, et al. Among authors: blind e. JAAD Case Rep. 2018 Jun 2;4(6):524-527. doi: 10.1016/j.jdcr.2018.05.002. eCollection 2018 Jul. JAAD Case Rep. 2018. PMID: 30023418 Free PMC article. No abstract available.

5

The European Medicines Agency's approval of new medicines for type 2 diabetes.

Blind E, Janssen H, Dunder K, de Graeff PA. Blind E, et al. Diabetes Obes Metab. 2018 Sep;20(9):2059-2063. doi: 10.1111/dom.13349. Epub 2018 May 30. Diabetes Obes Metab. 2018. PMID: 29740935 Free PMC article. Review.

6

Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.

Dunder K, de Graeff PA, Blind E. Dunder K, et al. Among authors: blind e. Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):129. doi: 10.1093/ehjcvp/pvx006. Eur Heart J Cardiovasc Pharmacother. 2017. PMID: 28444250 No abstract available.

7

CardioPulse: The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors.

Blind E, de Graeff PA, Meurs I, Holtkamp F, Baczynska A, Janssen H. Blind E, et al. Eur Heart J. 2016 Feb 7;37(6):502-3. doi: 10.1093/eurheartj/ehv685. Eur Heart J. 2016. PMID: 26853264 No abstract available.

8

The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors.

Blind E, de Graeff PA, Meurs I, Holtkamp F, Baczynska A, Janssen H. Blind E, et al. Eur Heart J. 2015 Dec 27:ehv673. doi: 10.1093/eurheartj/ehv673. Online ahead of print. Eur Heart J. 2015. PMID: 26712836 No abstract available.

9

Pancreatic safety of incretin-based drugs--FDA and EMA assessment.

Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C. Egan AG, et al. Among authors: blind e. N Engl J Med. 2014 Feb 27;370(9):794-7. doi: 10.1056/NEJMp1314078. N Engl J Med. 2014. PMID: 24571751 Free article. No abstract available.

10

Rosiglitazone: a European regulatory perspective.

Blind E, Dunder K, de Graeff PA, Abadie E. Blind E, et al. Diabetologia. 2011 Feb;54(2):213-8. doi: 10.1007/s00125-010-1992-5. Epub 2010 Dec 14. Diabetologia. 2011. PMID: 21153629 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

59 results

Search Page